FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
BREAKING NEWS
Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.
| READ NOW |
Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.
| READ NOW |